Comparison of Clinical Practice Guidelines for the Assessment and Management of Cutaneous Melanoma (Literature Review)
-
Hossein Gandomkar
,
Monireh Sadat Seyyedsalehi
,
Kazem Zendehdel
,
Abolfazl Salari
,
Mohammad Shirkhoda
Abstract
Evidence shows that there has been an increasing incidence of melanoma cancer in Iran, especially among the young population, which has led to increased mortality,disability and disablement, mostly due to the complications of disease and treatment.New treatments such as targeted therapy are extremely costly, and their results arenot clear.The objective of this study is to review different current guidelines for the management of cutaneous melanoma cancer and discuss the differences in the various phases of patient assessment (prevention, risk factors, genetic assessment, clinical diagnosis,biopsy, staging, treatment and follow-up, pediatric melanoma, melanoma duringpregnancy, and the necessity of social and mental support for melanoma patients).Then, based on the results, we will prepare a national guideline for the management of cutaneous melanoma in accordance with the prevailing conditions in Iran.
1. Moslehi R, Zeinomar N, Boscoe FP. Incidence of cutaneous malignant melanoma in Iranian provinces and American states matched on ultraviolet radiation exposure: an ecologic study. Environmental pollution (Barking, Essex : 1987). 2018;234:699-706.
2. clinical practice guidelines for the management of melanoma in Australia and new Zealand:(update). 2008.
3. nova scotia cancer care: Guidelines for the Management of Malignant Melanoma:(update). 2013.
4. Guidelines of care for the management of primary cutaneous melanoma (the American Academy of Dermatology). 2011.
5. AHRQ: Agency for healthcare research and quality. 2011.
6. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2015.
7. Evidence-based Clinical Practice Guideline: Treatment of Cutaneous Melanoma (American society of plastic surgeons). 2007.
8. NICE guideline: assessment and management of melanoma: (update). 2018.
9. NCCN guideline: clinical practice guideline in oncology melanoma: (Update). 2018.
10. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2018;31(1):24-38.
2. clinical practice guidelines for the management of melanoma in Australia and new Zealand:(update). 2008.
3. nova scotia cancer care: Guidelines for the Management of Malignant Melanoma:(update). 2013.
4. Guidelines of care for the management of primary cutaneous melanoma (the American Academy of Dermatology). 2011.
5. AHRQ: Agency for healthcare research and quality. 2011.
6. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2015.
7. Evidence-based Clinical Practice Guideline: Treatment of Cutaneous Melanoma (American society of plastic surgeons). 2007.
8. NICE guideline: assessment and management of melanoma: (update). 2018.
9. NCCN guideline: clinical practice guideline in oncology melanoma: (Update). 2018.
10. Cheng L, Lopez-Beltran A, Massari F, MacLennan GT, Montironi R. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2018;31(1):24-38.
| Files | ||
| Issue | Vol 11 No 1 (2019) | |
| Section | Reviews | |
| DOI | https://doi.org/10.18502/bccr.v11i1.1652 | |
| Keywords | ||
| Melanoma Treatment prevention cancer | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Gandomkar H, Seyyedsalehi MS, Zendehdel K, Salari A, Shirkhoda M. Comparison of Clinical Practice Guidelines for the Assessment and Management of Cutaneous Melanoma (Literature Review). Basic Clin Cancer Res. 2019;11(1):61-70.
